Yext에 대한 매도 수량은 투자자에게 Yext의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Yext (NYSE:YEXT) 주식, 공매도 수량 보고

Yext

Yext Inc provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and sync it to approximately 200 services including Apple Maps, Bing, Cortana, Facebook, Google, Google Maps, Instagram, Siri and Yelp. Digital knowledge is the structured information that a business wants to make publicly accessible. The company also makes search intelligent by helping to provide precise, accurate and current answers to location-based queries that are conducted across the web and mobile applications and voice and artificial intelligence, or AI, engines. The company derives the majority of its revenues from subscription services. Geographically, the company generates a majority of its revenue from North America and the rest from International markets.

Earnings

News

After-Hours Center

Movers

Tech

YEXT

옉스트(NYSE:YEXT)는 회사가 히어세이 시스템즈(Hearsay Systems)를 인수하겠다고 발표하고 월요일 1분기 재무 결과를 보고한 후 하락했다. 이 보고서에서 중요한 포인트를 살펴보자. 

옉스트: 히어세이 시스템즈 인수와 부진한 1분기 실적 발표 후 주가 급락

Pre-Market Outlook

Markets

Trading Ideas

CVGW

FCEL

GLBS

월요일 아침 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 일부 주식은 다음과 같다: 월스트리트는 칼라보 그로어스(NASDAQ:CVGW)가 시장 마감 후 1억 6,046만 달러의 매출과 주당 36센트의 분기 이익을 보고할 것으로 예상하고 있다. Benzinga Pro의 데이터에 따르면 칼라보 그로어스의 주가는 시간외 거래에서 0.4% 상승한 25.50달러를 기록했다. 

칼라보 그로어스, 퓨어셀 에너지 그리고 월요일 주목해야 할 주식 3종목

Yext Inc

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BJDX

SMST

LIFW

SMCX

LIFWW

Numinus Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.
<h3 class="wp-block-heading">Tech Partnership To Redefine Mental Health Clinics</h3>
In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.
"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said Payton Nyquvest, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."
<h3 class="wp-block-heading">Stella Takes Over Utah Operations</h3>
Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of $2.08 million, followed by $750,000 in installments throughout 2025, and up to $700,000 in deferred compensation.
"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated Michael Gershenzon, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."
<h3 class="wp-block-heading">An Asset-Light Business Model With Enhanced Focus</h3>
With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.
"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."
Cover image made with AI

Cannabis

Psychedelics

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Government

Politics

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

Here's the major earnings after the close today

Yext Non-GAAP EPS of $0.05 beats by $0.02, revenue of $97.89M misses by $0.25M

Yext, Inc. (YEXT) Q2 2025 Earnings Call Transcript

In a report released today, Tom White from D.A. Davidson maintained a Hold rating on Yext (YEXT – Research Report). The company's shares closed yes...

D.A. Davidson Sticks to Their Hold Rating for Yext (YEXT)

In a report released today, Rohit Kulkarni from Roth MKM maintained a Buy rating on Yext (YEXT – Research Report), with a price target of $7.50. Th...

Yext (YEXT) Gets a Buy from Roth MKM

Yext: Don't Buy This Dead Cat Bounce

Yext launches AI-powered social media management tool, Yext Social

Pegasystems's (PEGA) second-quarter results easily beat analysts' expectations. The company's long-term prospects appear bright with continuous innovation with AI and steady financial performance. So, let's analyze whether this is the software stock to buy now. Read more to find out... Pegasystems Inc. (<a href="https://stocknews.com/stock/PEGA/">PEGA</a>), a leading provider of enterprise software solutions, beat second-quarter top and bottom-line analyst expectations. The company posted a total revenue of $351.15 million, surpassing the consensus estimate of $324.69 million. Also, its non-GAAP EPS was $0.52 for the second quarter, compared to analysts' expectations of $0.29.
In the year 2024, Pegasystems introduced numerous ground-breaking, technology-efficient solutions for its diverse customer base. These innovations included Pega GenAI Knowledge Buddy, Pega GenAI Socrates, and Pega GenAI Blueprint. The company also expanded its strategic collaborations with companies like Amazon Web Services (AWS) and broadened its capabilities.
Also, amid the AI boom, the company continues to strive to integrate AI in its solutions. The global artificial intelligence (AI) market was valued at $638.23 billion in 2024 and is expected to total $3.68 trillion by 2034, exhibiting a <a href="https://www.precedenceresearch.com/artificial-intelligence-market#:~:text=The%20global%20artificial%20intelligence%20(AI)%20market%20size%20accounted%20for%20USD,19.1%25%20from%202024%20to%202034.">CAGR of 19.1%</a> from 2024 to 2034.
Alan Trefler, founder and CEO, said, "Our approach to statistical AI and generative AI continues to be a significant differentiator. The offerings we've introduced, especially Pega GenAI Blueprint&#x2122;, have captured the imagination of clients, prospects, and partners, allowing them to identify new possibilities and helping us drive deeper engagement."
He added, "With tens of thousands of blueprints created over the last few months, we're identifying opportunities to accelerate growth and creating additional momentum for Pega Cloud&#xAE;."
Shares of PEGA have gained 11% over the past six months and 70.3% over the past year to close its last trading session at $72.12.
Let's look at factors that could influence PEGA's performance in the upcoming months.
Recent Developments
On August 7, PEGA expanded its relationship with Amazon Web Services (AWS), where PEGA will leverage the AWS European Sovereign Cloud to deliver the Pega EU Service Boundary, a solution to help customers meet their most stringent digital sovereignty goals within the European Union (EU).
The new offering of the company will provide EU clients with further digital sovereignty controls.
On July 25, PEGA announced its latest milestone in advancing its federal agency capabilities by achieving FedRAMP&#xAE; high ready compliance and in-process status with the Department of Veterans Affairs for its Pega Cloud&#xAE; for government solutions.
Pega Cloud for Government is a fully managed cloud offering the tools, environments, and operational support to empower government agencies in developing applications optimized for government workloads.
Robust Financials
For the second quarter that ended June 30, 2024, PEGA's total revenue increased 17.7% year-over-year to $351.15 million, of which its subscription services revenue grew 8.8% from the year-ago value to $214.43 million.
Furthermore, the company's gross profit of $254.21 million indicates growth of 25.8% year-over-year. The company's non-GAAP net income and EPS came in at $45.84 million and $0.52, up 3711% and 5100% from the prior year's quarter, respectively.
As of June 30, 2024, PEGA's cash and cash equivalents stood at $258.26 million, compared to $229.90 million as of December 31, 2023.
Solid Historical Growth
PEGA's revenue grew at a CAGR of 8.6% over the past three years, while its net income improved at a CAGR of 103.5%. Its EPS increased at a CAGR of 96.6% over the same period, while the company's levered free cash flow grew at a CAGR of 36.3% over the same time frame.
Favorable Analyst Estimates
Analysts expect PEGA's revenue for the first quarter (ending March 2025) to come in at $355.13 million, indicating an increase of 7.6% year-over-year and the consensus EPS is expected to improve 11.6% year-over-year to $0.54 for the same period. Moreover, the company has surpassed the consensus EPS estimates in all of the trailing four quarters, which is impressive.
For the fiscal year (ending December 2024), the company's revenue is anticipated to grow 3.5% year-over-year to $1.48 billion, while its EPS is expected to grow 14.7% year-over-year to $2.84.
Favorable Profitability
PEGA's trailing-12-month <a href="https://www.investopedia.com/terms/g/gross_profit_margin.asp">gross profit margin</a> of 74.77% is 49.8% higher than the 49.90% industry average. The stock's trailing-12-month EBIT margin of 12.64% is significantly higher than the industry average of 4.83%. And the stock's trailing-12-month net income margin of 8.72% is 142.2% higher than the industry average of 3.60%.
Furthermore, the stock's ROCE, ROTC, and ROTA of 44.72%, 13.43%, and 8.45% favorably compares to the 4.55%, 2.65%, and 2.03% industry average, respectively.
POWR Ratings Appear Optimistic
PEGA's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, translating to a Strong Buy in our proprietary system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. PEGA has an A grade for Quality, consistent with its higher-than-industry profitability.
The stock also has a B grade for Growth and Sentiment, which is in sync with its robust financial performance in the last reported quarter and favorable analyst estimates.
PEGA is ranked #3 among the 39 stocks in the B-rated <a href="https://stocknews.com/category/software-business/">Software - Business</a> industry.
Beyond what I have stated above, we have also given PEGA grades for Stability, Momentum, and Value. Get access to all the PEGA ratings <a href="https://stocknews.com/stock/PEGA/">here</a>.
Bottom Line
PEGA reported better-than-expected earnings in the second quarter of fiscal 2024. Further, the company's long-term prospects appear promising, driven by its innovative product offerings, strategic expansion and investments, and technological innovations.
Given PEGA's solid revenue growth, promising analysts' expectations, and favorable profitability, supported by advancement in the AI industry and broadening opportunities, it could be ideal to invest in this stock.
How Does Pegasystems Inc. (PEGA) Stack Up Against Its Peers?
While PEGA has an overall POWR Rating of A, investors could also check out these other stocks within the A-rated <a href="https://stocknews.com/category/software-business/">Software - Business</a> industry with A (Strong Buy) or B (Buy) ratings:
Amdocs Ltd. (<a href="https://stocknews.com/stock/DOX/">DOX</a>), VMware Inc. (<a href="https://stocknews.com/stock/VMW/">VMW</a>), and Yext, Inc. (<a href="https://stocknews.com/stock/YEXT/">YEXT</a>)
For exploring more A and B-rated software stocks, <a href="https://stocknews.com/category/software-business/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
PEGA shares were trading at $73.60 per share on Wednesday afternoon, up $1.48 (+2.05%). Year-to-date, PEGA has gained 50.78%, versus a 20.95% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/pega-dox-vmw-yext-with-ai-booming-is-pegasystems-the-software-stock-to-buy/>With AI Booming, Is Pegasystems the Software Stock to Buy Now?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

With AI Booming, Is Pegasystems the Software Stock to Buy Now?

AVAV

CASY

CHPT

CPRT

DSGX

LAKE

PEGA

VRNT

Press Releases

Yext Once Again Revolutionizes the Listings Space with AI-Led Recommendations

Yext to Announce First Quarter Fiscal Year 2025 Financial Results on June 10, 2024

Yext to acquire Hearsay Systems

Yext Announces First Quarter Fiscal 2025 Results

Yext Announces Election of Mark Davis to its Board of Directors

Yext Completes Acquisition of Hearsay Systems

Yext to Announce Second Quarter Fiscal Year 2025 Financial Results on September 4, 2024

Yext Announces Second Quarter Fiscal 2025 Results

Introducing Yext Social: A New AI-Powered Standard in Local Social Engagement

Yext Expands AI Review Generation to Include Third-Party Sites

Amplitude

Blend Labs

Bit Digital

Bitdeer Technologies Group - Ordinary Shares

Bitdeer Technologies

Consensus Cloud Solutions, Inc. - Common Stock

Consensus Cloud Solns

Daily Journal Corp. (S.C.) - Common Stock

Daily Journal

Digimarc

Enfusion

E2open Parent Holdings, Inc.Class A Common Stock

E2open Parent Holdings

BitFuFu

AMTD Digital Inc. American Depositary Shares (every five of which represent two Class A Ordinary Shares)

AMTD Digital

Karooooo

MeridianLink

Matterport

NextNav

Opera Limited - American Depositary Shares

Opera

Pagaya Technologies Ltd. - Class A Ordinary Shares

Pagaya Techs

Pros Holdings

Red Violet

Riskified

Sprout Social, Inc - Class A Common Stock

Sprout Social

Tuya Inc. American Depositary Shares, each representing one Class A Ordinary Share

Comments

Yext

매도 수량

Yext (NYSE:YEXT) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌